Shanghai Pharmaceuticals Valuation Multiples
Discover Shanghai Pharmaceuticals' revenue and EBITDA valuation multiples and M&A history.
Shanghai Pharmaceuticals Overview
About Shanghai Pharmaceuticals
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2024, medical distribution is the largest segment, accounting for 91.3% of total revenue. It also has coverage of 31 provinces and cities nationwide.
Founded
1994
HQ
Employees
49.4K
Website
Financials (LTM)
EV
$11B
Valuation Multiples
Start free trial
Shanghai Pharmaceuticals Financials
Shanghai Pharmaceuticals reported last 12-month revenue of $43B and EBITDA of $1.9B.
In the same LTM period, Shanghai Pharmaceuticals generated $4.9B in gross profit, $1.9B in EBITDA, and $843M in net income.
Shanghai Pharmaceuticals P&L
In the most recent fiscal year, Shanghai Pharmaceuticals reported revenue of $42B and EBITDA of $2.1B.
Shanghai Pharmaceuticals is profitable as of last fiscal year, with gross margin of 11%, EBITDA margin of 5%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
Shanghai Pharmaceuticals Stock Performance
Shanghai Pharmaceuticals has current market cap of $8.1B, and enterprise value of $11B.
Shanghai Pharmaceuticals' stock price is $2.43.
Shanghai Pharmaceuticals has an EPS (earnings per share) of $0.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11B | $8.1B | -0.2% | - | - | - | $0.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialShanghai Pharmaceuticals Valuation Multiples
Shanghai Pharmaceuticals trades at 0.3x EV/Revenue multiple, and 6.0x EV/EBITDA.
Shanghai Pharmaceuticals Financial Valuation Multiples
As of September 3, 2026, Shanghai Pharmaceuticals has market cap of $8.1B and EV of $11B.
Shanghai Pharmaceuticals has a P/E ratio of 9.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Shanghai Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Shanghai Pharmaceuticals Margins & Growth Rates
Shanghai Pharmaceuticals grew revenue by 5% but EBITDA decreased by 4% in the last fiscal year.
In the most recent fiscal year, Shanghai Pharmaceuticals reported gross margin of 11%, EBITDA margin of 5%, and net margin of 2%.
Shanghai Pharmaceuticals Margins
Shanghai Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Shanghai Pharmaceuticals Operational KPIs
Shanghai Pharmaceuticals' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.1M for the same period.
Shanghai Pharmaceuticals' Rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shanghai Pharmaceuticals' Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Shanghai Pharmaceuticals Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Shanghai Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Shanghai Pharmaceuticals
Shanghai Pharmaceuticals has acquired 1 company to date.
Last acquisition by Shanghai Pharmaceuticals was on August 4th 2016. Shanghai Pharmaceuticals acquired Vitaco Holdings for undisclosed valuation.
Latest Acquisitions by Shanghai Pharmaceuticals
| Description | Vitaco Holdings is an Australasian manufacturer and marketer of vitamins, nutritional supplements and sports nutrition products. Its brands include Musashi, Nutra-Life, Healtheries and Aussie Bodies, made and distributed from Australian operations at North Ryde in Sydney and New Zealand operations in Auckland, and sold through grocery, pharmacy and health food channels in Australasia and Asia. The company listed on the ASX in September 2015 and was taken private in December 2016. |
| HQ Country |  |
| HQ City | Sydney |
| Deal Date | 4 Aug 2016 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Shanghai Pharmaceuticals acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Shanghai Pharmaceuticals
| When was Shanghai Pharmaceuticals founded? | Shanghai Pharmaceuticals was founded in 1994. |
| Where is Shanghai Pharmaceuticals headquartered? | Shanghai Pharmaceuticals is headquartered in China. |
| How many employees does Shanghai Pharmaceuticals have? | As of today, Shanghai Pharmaceuticals has over 49K employees. |
| Is Shanghai Pharmaceuticals publicly listed? | Yes, Shanghai Pharmaceuticals is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Shanghai Pharmaceuticals? | Shanghai Pharmaceuticals trades under 601607 ticker. |
| When did Shanghai Pharmaceuticals go public? | Shanghai Pharmaceuticals went public in 1994. |
| Who are competitors of Shanghai Pharmaceuticals? | Shanghai Pharmaceuticals main competitors include |
| What is the current market cap of Shanghai Pharmaceuticals? | Shanghai Pharmaceuticals' current market cap is $8.1B. |
| What is the current revenue of Shanghai Pharmaceuticals? | Shanghai Pharmaceuticals' last 12 months revenue is $43B. |
| What is the current revenue growth of Shanghai Pharmaceuticals? | Shanghai Pharmaceuticals revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Shanghai Pharmaceuticals? | Current revenue multiple of Shanghai Pharmaceuticals is 0.3x. |
| What is the current EBITDA of Shanghai Pharmaceuticals? | Shanghai Pharmaceuticals' last 12 months EBITDA is $1.9B. |
| What is Shanghai Pharmaceuticals' EBITDA margin? | Shanghai Pharmaceuticals' last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Shanghai Pharmaceuticals? | Current EBITDA multiple of Shanghai Pharmaceuticals is 6.0x. |
| What is the current FCF of Shanghai Pharmaceuticals? | Shanghai Pharmaceuticals' last 12 months FCF is $471M. |
| What is Shanghai Pharmaceuticals' FCF margin? | Shanghai Pharmaceuticals' last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Shanghai Pharmaceuticals? | Current FCF multiple of Shanghai Pharmaceuticals is 24.0x. |
| How many companies Shanghai Pharmaceuticals has acquired to date? | As of September 2026, Shanghai Pharmaceuticals has acquired 1 company. |
| What was the largest acquisition by Shanghai Pharmaceuticals? | None of the M&A deals Shanghai Pharmaceuticals has completed have disclosed valuations. |
| What companies Shanghai Pharmaceuticals acquired? | Shanghai Pharmaceuticals acquired Vitaco Holdings. |
| In how many companies Shanghai Pharmaceuticals has invested to date? | Shanghai Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Shanghai Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.